e-learning
resources
Vienna 2009
Wednesday, 16.09.2009
What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Identification and analysis of rare and novel mutations of the alpha-1-antitrypsin gene
C. Herr, R. Koczulla, V. Kotke, C. Vogelmeier, R. Bals (Marburg, Germany)
Source:
Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Session:
What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Session type:
E-Communication Session
Number:
4761
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Herr, R. Koczulla, V. Kotke, C. Vogelmeier, R. Bals (Marburg, Germany). Identification and analysis of rare and novel mutations of the alpha-1-antitrypsin gene. Eur Respir J 2009; 34: Suppl. 53, 4761
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Identification and characterisation of twenty-two novel SERPINA1 pathological mutations
Source: Virtual Congress 2020 – Genetic and environmental influences on development of asthma and COPD
Year: 2020
Structural and clinical characterization of novel missense variants of SERPINA1 gene causing alpha-1 antitrypsin deficiency
Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases
Year: 2019
Identification and characterisation of seven novel SERPINA1 null mutations
Source: International Congress 2014 – Genes and environment in asthma and COPD
Year: 2014
Identification of novel rare genetic variants associated with COPD in the general population
Source: International Congress 2018 – Multiomics studies in epidemiology: what can they tell us?
Year: 2018
Genetic analysis of two novel mucin-like genes in the disease-susceptibility locus for diffuse panbronchiolitis
Source: Annual Congress 2011 - Genetics of airway diseases and treatment
Year: 2011
Large phenotypic spectrum associated with two new deep intronic variants on the CFTR gene
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018
Novel genetic variants in alpha-1 antitripsin deficiency cases carrying S alleles and discordant genotype and serum levels
Source: International Congress 2015 – Promising novel findings in translational pulmonary research
Year: 2015
Positional cloning on 19q13 identifies
UPAR
as a potential asthma susceptibility gene
Source: Eur Respir J 2007; 30: Suppl. 51, 37s
Year: 2007
Sarcoidosis is associated with a truncating splice site mutation in the
BTNL2
gene
Source: Eur Respir J 2005; 26: Suppl. 49, 468s
Year: 2005
Molecular characterization of novel PiS-like alleles identified in Spanish patients with Alpha-1 antitrypsin deficiency
Source: International Congress 2018 – Functional genomics and COPD: new challenges
Year: 2018
Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program
Source: Annual Congress 2007 - Lung function and therapy in obstructive lung diseases
Year: 2007
Haploid genetic screening identifies a novel regulator of BMPR2
Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension
Year: 2020
Target other gene point mutations: HER2 and rare EGFR mutations
Source: ERS Research Seminar
Year: 2015
New method of Alpha-1-antitrypsin diagnosis facilitates the detection of rare mutations
Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases
Year: 2020
Candidate surrogate markers for COPD identified by differential gene expression
Source: Eur Respir J 2002; 20: Suppl. 38, 583s
Year: 2002
SERPINA1 gene variants in subjects from a general population with reduced alpha1-antitrypsin level
Source: Annual Congress 2008 - COPD
Year: 2008
Variable phenotype associated with SP-C gene mutations: fatal case with the I73T mutation
Source: Eur Respir J 2004; 24: 1072-1073
Year: 2004
Description of new CFTR gene’s mutations in patients of Russia
Source: Virtual Congress 2020 – Cystic fibrosis
Year: 2020
Prevalence and phenotype of subjects carrying rare variants in Argentina for alpha1-antitrypsin deficiency
Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept